Results 41 to 50 of about 510 (116)
Angiogenesis and Progression in Human Melanoma
Dermatology Research and Practice, Volume 2010, Issue 1, 2010., 2010 In tumor growth, angiogenesis, the process of new‐formation of blood vessels from pre‐existing ones, is uncontrolled and unlimited in time. The vascular phase is characterized by the new‐formation of vascular channels that enhances tumor cell proliferation, local invasion and hematogenous metastasis.
R. Ria +7 more
wiley +1 more source
, 2001 The present study was aimed at evaluating the effect of the matrix metalloproteinase (MMP) inhibitor prinomastat (AG3340) on tumor progression using an orthotopic pancreatic carcinoma model in severe combined immunodeficient mice.
Hellmut Augustin +13 more
core +1 more source
Targeting Tumor Stroma: Current Challenges and Future Directions
MedComm, Volume 7, Issue 5, May 2026.Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang +7 more
wiley +1 more source
Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma
Journal of Oncology, Volume 2010, Issue 1, 2010., 2010 Despite advances in surgery, radiation therapy, and chemotherapeutics, patients with malignant glioma have a dismal prognosis. The formations of aberrant tumour vasculature and glioma cell invasion are major obstacles for effective treatment. Angiogenesis is a key event in the progression of malignant gliomas, a process involving endothelial cell ...
Ruman Rahman +4 more
wiley +1 more source
Overview of the CYP2D6 ligands.
, 2018 Three substrates (tamoxifen, veliparib, and bufuralol) and two inhibitors (prinomastat and quinidine) were used in this study. The red asterisk indicates the primary site of metabolism (SoM, S4 Fig), and the black asterisk a secondary SoM.
Charleen G. Don (5675906) +1 more
core +1 more source
Mass spectrometry in ocular drug research
Mass Spectrometry Reviews, Volume 45, Issue 1, Page 37-68, January/February 2026.Abstract Mass spectrometry (MS) has been proven as an excellent tool in ocular drug research allowing analyzes from small samples and low concentrations. This review begins with a short introduction to eye physiology and ocular pharmacokinetics and the relevance of advancing ophthalmic treatments.
Eva M. del Amo +6 more
wiley +1 more source
CYP2D6 x-ray structures illustrating the conformational diversity (open/closed).
, 2018 The apo structure 2F9Q (left) shows a more open conformation as defined by the distances between the FG- (grey), BC- (cyan) and AB- (pink) loops. The holo 3QM4 complex (with prinomastat, right) represents one of the most closed CYP2D6 conformations ...
Charleen G. Don (5675906) +1 more
core +1 more source
Backbone root mean square deviation (RMSD) graphs for all CYP2D6 simulations.
, 2018 The wild-type simulation is shown black in all graphs. The convergence time varied between 20 ns ≤ t ≤ 250 ns. Compared to the wild-type apo simulations; low degree of fluctuation was observed for wild-type veliparib (wt_vel), quinidine (wt_qui), and ...
Charleen G. Don (5675906) +1 more
core +1 more source
Advanced Science, Volume 11, Issue 32, August 27, 2024.The revolutionary nanotechnology brings hope to posterior segment ocular diseases. This review delves into the challenges of conventional drug delivery and the advantages of diverse nanomaterials in enhancing drug stability, targeting, and permeability by targeting VEGF, ROS, macrophages.
Yue Wu +11 more
wiley +1 more source
Dominant ligand conformations during 1
, 2018 (A-C) Prinomastat (inhibitor) binding mode is displayed for wild-type (A), CYP2D6*17 (B) and CYP2D6*53 (C). (D-F) quinidine (inhibitor) binding mode is displayed for wild-type (D), CYP2D6*17 (E) and CYP2D6*53 (F).
Charleen G. Don (5675906) +1 more
core +1 more source